The agreement provides concrete near-term revenue visibility and a significant expansion of the CDMO order book. Monitor upcoming quarterly filings for revenue recognition from this contract and any conversion of the $5.85 million indicative pipeline into firm orders.
Price Chart
Executive Summary
Scinai Immunotherapeutics announced a $5.1 million definitive development and clinical manufacturing CDMO agreement with a U.S. Nasdaq-listed biopharma company, expanding a prior engagement. Committed Customer Orders surged ~300% to ~$7.6 million from $1.9 million at year-end 2025, with potential additional uncommitted work valued at $5.85 million. The deal provides near-term revenue visibility for 2026-2027 and materially expands the contracted CDMO pipeline.
Key Facts
- Definitive CDMO agreement valued at approximately $5.1 million in committed base service fees.
- Committed Customer Orders reached ~$7.6 million, up ~300% from $1.9 million at year-end 2025 and more than double the ~$3.1 million reported as of August 16, 2026.
- Potential additional uncommitted clinical manufacturing has an indicative value of $5.85 million for late 2027 through H1 2028.
- Services cover CMC development and clinical manufacturing for an investigational oncology product, with IND-enabling activities in 2026 and clinical manufacturing planned to begin January 2027.
- Advance and milestone payments expected to support cash flow and working capital during project execution.
- Customer is a U.S.-based, Nasdaq-listed biopharmaceutical company.
Financial Impact
$5.1 million committed service fees, with Committed Customer Orders at ~$7.6 million (up ~300% YoY). Potential additional uncommitted work of $5.85 million.
Risk Factors
- The $5.1 million commitment is subject to performance and termination rights; projects may be delayed or modified.
- Potential additional $5.85 million in services is uncommitted and subject to final scope, pricing, and customer development progress.
- Revenue recognition and cash flow timing depend on milestone achievement and accounting requirements.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-108730 |
| Document: ea0308438-6k_scinai.htm | 0001213900-26-108730 |
| Document: 0001213900-26-108730-index-headers.html | 0001213900-26-108730 |
| Document: 0001213900-26-108730-index.html | 0001213900-26-108730 |
| Document: 0001213900-26-108730.txt | 0001213900-26-108730 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 7d ago | 6-K | $0.6813 | awaiting T+60 | — | $0.5310 (−22.06%) |
Oct 16, 2026 11d ago | 6-K | $0.7520 | awaiting T+60 | — | $0.5310 (+29.39%) |
Oct 16, 2026 11d ago | Press Release | $0.7524 | awaiting T+60 | — | $0.5310 (+29.43%) |
Oct 15, 2026 12d ago | 6-K | $0.9015 | awaiting T+60 | — | $0.5310 (+41.10%) |
Oct 13, 2026 14d ago | 6-K | $1.23 | awaiting T+60 | — | $0.5310 (−56.83%) |
Oct 6, 2026 21d ago | EFFECT | $1.22 | awaiting T+60 | — | $0.5310 (+56.48%) |
Sep 21, 2026 5w ago | 6-K | $1.69 | awaiting T+60 | — | $0.5310 (−68.58%) |
Aug 26, 2026 8w ago | 6-K | $2.87 | awaiting T+60 | — | $0.5310 (+81.50%) |
Aug 19, 2026 9w ago | 6-K | $0.2740 | awaiting T+60 | — | $0.5310 (−93.80%) |
Jun 17, 2026 18w ago | 6-K | $0.3370 $0.2440 | ▼ −27.60% | ▼ −30.28% | $0.5310 (+57.57%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers